Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

idrabiotaparinux

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BiotinOligosaccharides
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale.
Covering: up to November 2013. Heparin and heparan sulfate are natural polysaccharides with strong structural variations, which… Expand
Highly Cited
2012
Highly Cited
2012
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority…
BACKGROUND Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2011
Highly Cited
2011
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis
Summary.  Background: Idraparinux, a long acting inhibitor of factor (F) Xa, is as effective as standard anticoagulant therapy… Expand
2011
2011
Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?
The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Highly Cited
2010
Highly Cited
2010
Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion
Summary.  Background:  Idraparinux is an inhibitor of activated factor X (FXa) with a long half‐life allowing once‐weekly dosing… Expand
2010
2010
Idraparinux and idrabiotaparinux
  • J. Harenberg
  • Expert review of clinical pharmacology
  • 2010
    • Corpus ID: 207209495
Idraparinux is a polymethylated synthetic pentasaccharide that binds to antithrombin with high affinity. Idrabiotaparinux is a… Expand
Review
2010
Review
2010
Potential of new anticoagulants in patients with cancer.
  • J. Weitz
  • Thrombosis research
  • 2010
    • Corpus ID: 31157750
Cancer-associated thrombosis is a major cause of morbidity and mortality. Although anticoagulation remains the mainstay for… Expand
  • table 1
  • table 2
Review
2009
Review
2009
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
  • J. Harenberg
  • Thrombosis and haemostasis
  • 2009
    • Corpus ID: 10817514
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. It was designed for weekly, rather than… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
2009
2009
The pharmacokinetics of idraparinux, a long‐acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials
Summary.  Background: Idraparinux, a long‐acting synthetic pentasaccharide, is a specific antithrombin‐dependent inhibitor of… Expand
2008
2008
Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin
Idrabiotaparinux is a novel synthetic anticoagulant that links idraparinux, a specific, indirect factor Xa inhibitor, to biotin… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE